Review of rifaximin as treatment for SIBO and IBS
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Rifaximin is a broad-range, gastrointestinal-specific antibiotic that demonstrates no clinically relevant bacterial resistance. Therefore, rifaximin may be useful in the treatment of gastrointestinal disorders associated with altered bacterial flora, including irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO). OBJECTIVE: To review rifaximin for treatment of IBS and SIBO. METHODS: Review of rifaximin clinical trials. RESULTS/CONCLUSION: Rifaximin improved global symptoms in 33 - 92% of patients and eradicated SIBO in up to 84% of patients with IBS, with results sustained up to 10 weeks post-treatment. Rifaximin caused a lower number of adverse events compared with metronidazole or levofloxacin and may have a more favorable adverse event profile than systemic antibiotics, without clinically relevant antibiotic resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The burden of selected digestive diseases in the United States
Sandler, R. S., Everhart, J. E., Donowitz, M., Adams, E., Cronin, K., Goodman, C., Gemmen, E., Shah, S., Avdic, A., & Rubin, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.32978 · Cited by 1,512
Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780 · cited 4×
“, neomycin, metronidazole, ciprofloxacin) eradicated SIBO and improved bowel symptoms; these results further support a causal role of bacteria in IBS [10-12,16,18,19,21] .”
BackgroundResultSelf-citationIrritable bowel syndrome in the United States: prevalence, symptom patterns and impact
Hungin, A. P. S., Chang, L., Locke, G. R., Dennis, E. H., & Barghout, V. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02463.x · Cited by 494 · cited 3×
“Although only about 50% of patients with IBS report seeking medical attention for their symptoms [3] , IBS is one of the most frequently seen medical conditions in primary care and is the most common reason for consulting a gastroenterologist [1] .”
BackgroundSmall Intestinal Bacterial Overgrowth: A Framework for Understanding Irritable Bowel Syndrome
Lin, H. C. (2004) · JAMA · doi:10.1001/jama.292.7.852 · Cited by 396 · cited 2×
“Increasing evidence of the role of SIBO in IBS [2,9-24] , as well as the efficacy of antibiotics in relieving SIBO, has led to investigations of rifaximin as a potential treatment for SIBO and mild-to-moderate IBS-C.”
BackgroundSharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S., & ElHajj, I. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00458.x · Cited by 344
Yang, J., Lee, H.-R., Low, K., Chatterjee, S., & Pimentel, M. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-9839-8 · Cited by 129
Self-citationGrover, M., Kanazawa, M., Palsson, O. S., Chitkara, D. K., Gangarosa, L. M., Drossman, D. A., & Whitehead, W. E. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01142.x · Cited by 111
Lembo, A., Zakko, S. F., Ferreira, N. L., Ringel, Y., Bortey, E., Courtney, K., Corsi, E., Forbes, W. P., & Pimentel, M. (2008) · Gastroenterology · doi:10.1016/s0016-5085(08)62544-5 · Cited by 77
Self-citationEsposito, I. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.13.6016 · Cited by 28 · cited 4×
“, neomycin, metronidazole, ciprofloxacin) eradicated SIBO and improved bowel symptoms; these results further support a causal role of bacteria in IBS [10-12,16,18,19,21] .”
BackgroundResultInfluential
Cited by
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Self-citationSmall intestinal bacterial overgrowth syndrome
Bures, J. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i24.2978 · Cited by 620
The brain-gut axis in abdominal pain syndromes.
Mayer, E. A., & Tillisch, K. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-012309-103958 · Cited by 511
A role for the gut microbiota in IBS
Collins, S. M. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.40 · Cited by 351
Menees, S. B., Maneerattannaporn, M., Kim, H. M., & Chey, W. D. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.355 · Cited by 283
Metadata
- Authors
- Pimentel, M.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2009-03
- Volume
- 18
- Issue
- 3
- Pages
- 349-358
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2052689271
- Cited by
- 122
- References
- 9
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.